https://www.selleckchem.com/pr....oducts/FK-506-(Tacro
The most common reason for discontinuation was patient refusal and the most frequent medication prescribed after discontinuation was paliperidone palmitate one-monthly (PP1M). Post hoc, we analysed outcome in those continuing any form of PPLAI (those continuing with PP3M and those switching back to PP1M). Continuation over 2 years with any PPLAI formulation was 73% (81/111) and relapse was recorded in 9% (10/111). Overall, PP3M was an effective maintenance treatment for schizophrenia after stabilisation on PP1M in a clinical
Like
Comment
Share
